Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer

Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer

Abstract Background Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aimed at retrospectively evaluating interobserver agreement of [68Ga]Ga-PS...

Full description

Bibliographic Details
Main Authors:	Céline Derwael, Olivier Lavergne, Pierre Lovinfosse, Vlad Nechifor, Mallory Salvé, David Waltregny, Roland Hustinx, Nadia Withofs
Format:	Article
Language:	English
Published:	SpringerOpen 2020-02-01
Series:	EJNMMI Research
Subjects:	Interobserver agreement PSMA-RADS PROMISE miTNM PSMA PET Standardized evaluation
Online Access:	http://link.springer.com/article/10.1186/s13550-020-0596-4

Similar Items

Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
by: Sebastian Hoberück, et al.
Published: (2021-10-01)

PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score
by: Francesco Dondi, et al.
Published: (2023-02-01)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
by: Hui Wang, et al.
Published: (2021-08-01)

Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators
by: Elke A. van Brandwijk, et al.
Published: (2024-04-01)

Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow)
by: Else A. Aalbersberg, et al.
Published: (2020-05-01)

Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
by: Courtney Lawhn-Heath, et al.
Published: (2020-10-01)

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis
by: Cristina E. Popescu, et al.
Published: (2024-04-01)

[68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
by: Peter Truckenmueller, et al.
Published: (2022-09-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with <sup>68</sup>Ga-PSMA PET/CT Features in Primary Staging
by: Luigia Vetrone, et al.
Published: (2023-03-01)

Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
by: Melissa E. Rodnick, et al.
Published: (2020-11-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
by: Hinke Siebinga, et al.
Published: (2023-06-01)

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01)

Imageological/Structural Study regarding the Improved Pharmacokinetics by <sup>68</sup>Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer
by: Huihui Zhang, et al.
Published: (2023-04-01)

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
by: Amir Iravani, et al.
Published: (2017-12-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

Intra-Individual Comparison of Physiologic [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
by: Emil Novruzov, et al.
Published: (2023-05-01)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
by: Florian Rosar, et al.
Published: (2022-05-01)

Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
by: Jing Zhao, et al.
Published: (2020-12-01)

Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
by: K.S. Ajish Kumar, et al.
Published: (2021-12-01)

Active Lumbar Spondylodiscitis on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
by: Florian Rosar, et al.
Published: (2023-12-01)

Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
by: Daniel Groener, et al.
Published: (2023-01-01)

Dependence of Renal Uptake on Kidney Function in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Imaging
by: Falk Gühne, et al.
Published: (2024-03-01)

Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis
by: Andrei Gafita, et al.
Published: (2019-12-01)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT
by: Daniel Groener, et al.
Published: (2023-07-01)

Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
by: Conrad Leitsmann, et al.
Published: (2021-03-01)

Optimization of injected 68Ga-PSMA activity based on list-mode phantom data and clinical validation
by: J. Wielaard, et al.
Published: (2020-04-01)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020-11-01)

Comparison of Multiparametric MRI, [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT, and Clinical Nomograms for Primary T and N Staging of Intermediate-to-High-Risk Prostate Cancer
by: Omar Marek Tayara, et al.
Published: (2023-12-01)

Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
by: Thomas Franz Fassbender, et al.
Published: (2020-06-01)

Direct Patlak Reconstruction of [<sup>68</sup>Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study
by: Sazan Rasul, et al.
Published: (2023-09-01)

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
by: André H. Dias, et al.
Published: (2023-04-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)

Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent—Impact of Delayed Imaging
by: Jolanta Kunikowska, et al.
Published: (2022-06-01)

Analysis of Pros and Cons in Using [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
by: Costantina Maisto, et al.
Published: (2022-06-01)

A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [68Ga]Ga-PSMA-11
by: Steve S. Huang, et al.
Published: (2024-01-01)

Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
by: Esmée C. A. van der Sar, et al.
Published: (2022-08-01)